Long-Term Use of 5α-Reductase Inhibitors and the Risk of Male Breast Cancer

    August 2014 in “ Cancer Causes & Control ”
    Ruben G. Duijnhoven, Sabine M. J. M. Straus, Patrick C. Souverein … Marie L. De Bruin
    Studysummary In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride The Journal of Urology · 2013
    2. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia The New England Journal of Medicine · 2003
    3. Dihydrotestosterone and the Concept of 5-Alpha-Reductase Inhibition in Human Benign Prostatic Hyperplasia European Urology · 2000
    4. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1998